A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure

OBJECTIVE: To investigate whether the Multi‐Biomarker Disease Activity (MBDA) score predicts optimal add‐on treatment in patients with early rheumatoid arthritis (RA) who were inadequate responders to MTX (MTX‐IRs). METHODS: We analyzed data from 157 MTX‐IRs (with a Disease Activity Score using the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hambardzumyan, Karen, Saevarsdottir, Saedis, Forslind, Kristina, Petersson, Ingemar F., Wallman, Johan K., Ernestam, Sofia, Bolce, Rebecca J., van Vollenhoven, Ronald F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516230/
https://www.ncbi.nlm.nih.gov/pubmed/27992691
http://dx.doi.org/10.1002/art.40019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516230/
https://www.ncbi.nlm.nih.gov/pubmed/27992691
http://dx.doi.org/10.1002/art.40019

Ejemplares similares